The Prognosis of Acute Myocardial Infarction

The objective of this study is to establish a comprehensive registry and surveillance system for acute myocardial infarction (AMI) patients in Xinjiang. This platform is designed to support clinical research and translational medicine, aiming to improve the quality of AMI patient care through the integration of guideline recommendations into clinical practice. By collecting detailed information on patient demographics, characteristics, diagnostic methods, treatment programs, and outcomes, including mortality, complications, hospitalization costs, and follow-up events such as death and major adverse cardiac events, this study seeks to lay the foundation for future quality improvement initiatives and research. The ultimate goal is to translate research findings into improved care practices for AMI patients, thereby reducing morbidity and mortality associated with the condition. This endeavor will bridge the gap between clinical research and practical healthcare delivery, ensuring that advancements in the treatment and management of AMI directly benefit patients in Xinjiang, contributing to substantial improvements in healthcare outcomes.

Inclusion criteria

Acute myocardial infarction patients in hospitalized of the First Affiliated Hospital of Xinjiang Medical University (include diagnosed acute ST-elevation or non ST-elevation myocardial infarction).Diagnosis criteria must meet Universal Definition for AMI (2012).

Exclusion criteria

• Combined with severe valvular heart disease;
• Combined with severe congenital heart disease;
• Combined hyperthyroidism, anemia and other high-powered heart disease;
• With pulmonary heart disease;
• With hypertrophic obstructive cardiomyopathy;
• Severe hypotension (SBP <90mmHg or DBP <60mmHg at enrollment);
• Uncontrolled hypertension (SBP> 160 mmHg before PCI, and / or DBP> 100 mmHg);
• Liver dysfunction (defined as ALT or total bilirubin is greater than the normal upper limit of 3 times);
• Renal insufficiency (defined as serum creatinine greater than 1.5 times the normal upper limit);
• High-risk bleeding patients, such as thrombocytopenia, blood diseases and other diseases;
• active peptic ulcer and skin ulcers;
• A patient who is allergic to clopidogrel, tegrellol, or aspirin;
• Patients with a history of cardiogenic shock within two weeks;
• pregnant and lactating women, during treatment can not be strict contraception of women of childbearing age;
• In the past 3 months participated in other clinical researchers;
• Persons who do not have legal or legal competence;
• Any condition that the investigator considers unsuitable for participation in the clinical study.